MLND News and Press, Millendo Therapeutics From 11/07/19

– Prominent PWS clinical expert along with company management will discuss disease epidemiology, current treatment landscape and livoletide as a potential new therapy for PWS patients – – Live webcast to begin at 8:30 a.m. EST – Millendo Therapeutics, ...

Presentations on livoletide and PWS at the Foundation for Prader-Willi Research Annual Research Symposium and Family Conference and the Prader-Willi Syndrome Association USA National Convention Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company dev...

Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, today announced that senior management will present company overviews and conduct one-on-one investor meetings at the following healthcare invest...

The following slide deck was published by Millendo Therapeutics, Inc. in conjunction with this Read more ...

Millendo Therapeutics (NASDAQ: MLND ): Q2 GAAP EPS of -$0.74 beats by $0.07 . Cash, cash equivalents, marketable securities and restricted cash of $56.63M Press Release More news on: Millendo Therapeutics, Inc., Earnings news and commentary, ,

  – Livoletide pivotal study in Prader-Willi syndrome (ZEPHYR) on track to report topline results in 1H20 – – Nevanimibe CAH Phase 2b study now enrolling under amended protocol – – New program, MLE-301, beginning preclinical development to e...

Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, today announced that management will present company overviews and conduct one-on-one investor meetings at the following healthcare investor conf...

Blueprint Medicines (NASDAQ: BPMC ) initiated with Outperform rating and $120 (22% upside) price target at Baird. More news on: Blueprint Medicines Corporation, Millendo Therapeutics, Inc., HealthEquity, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Millendo Therapeutics (NASDAQ: MLND ) initiated with Outperform rating and $26 (141% upside) at Oppenheimer. More news on: Viking Therapeutics, Inc., Millendo Therapeutics, Inc., Laboratory Corporation of America Holdings, Healthcare stocks news, Stocks on the move, , Read more ...

Quick Take BridgeBio ( BBIO ) has filed to raise gross proceeds of up to $225 million from a U.S. IPO, according to an S-1/A registration statement . The group is developing therapeutics for Mendelian diseases, or diseases arising from defects in a single gene as well as cancers with clea...